The AGL Knockout HeLa Polyclonal Cells provide a CRISPR/Cas9-mediated loss-of-function model of the AGL gene within a heterogeneous HeLa polyclonal population. This gene-edited pool offers a diverse cellular repertoire lacking glycogen debranching enzyme. Unlike monoclonal lines, the polyclonal format captures biological variability, enabling robust interrogation of AGL-dependent processes across varied knockout efficiencies and contexts. It is suited for pooled functional screens, population-level metabolic studies, and experiments requiring avoidance of clonal artifacts.
HeLa cells are an immortalized human cervical carcinoma epithelial line, originally derived from an HPV-18-positive adenocarcinoma. They are a cornerstone model in cell biology, cancer research, and drug development, offering well-characterized growth and metabolic profiles. Their robust proliferation and genetic tractability make them ideal for studying fundamental mechanisms, including metabolic reprogramming. The extensive existing literature and standardized protocols enhance the utility of HeLa-based knockout models.
AGL encodes glycogen debranching enzyme (GDE), which hydrolyzes ??-1,6-glycosidic bonds in glycogen and phosphorylase limit dextrin, enabling complete glycogen breakdown. GDE functions coordinately with glycogen phosphorylase (PYGL) to release glucose-1-phosphate and free glucose. AGL activity is regulated by insulin, glucagon, and AMPK signaling, and it interacts with glycogen synthase (GYS1) and phosphoglucomutase (PGM1). Disruption of AGL ablates debranching, causing accumulation of limit dextrin and impaired glycogen mobilization.
In HeLa cervical carcinoma cells, AGL knockout creates a model to explore glycogen metabolism in cancer. HeLa cells exhibit high glycolytic flux and metabolic reprogramming. Loss of GDE disrupts glycogen homeostasis, potentially altering energy balance and biosynthetic precursors. This model allows dissection of glycogen’s role in tumor cell proliferation, stress resilience, and metabolic plasticity, with the polyclonal population better reflecting tumor microenvironment heterogeneity.
Applications include studying glycogen storage disease type III, cancer metabolism, and the role of glycogen in cell proliferation. Assays include glycogen content measurement, PAS staining, GDE enzyme activity assays, and metabolite profiling of glucose and glucose-1-phosphate. Western blot and RT-qPCR can confirm AGL loss and monitor PYGL and GYS1 expression. The cells support small-molecule screening and genetic interaction studies. For inquiries, please contact Ascent Research.
